Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
An assay procedure for measuring plasma and urine levels of canrenone is described. The drug is extracted with n-hexane-toluene (1:1, v/v) after adding spirorenone as internal standard, and is then separated from plasma constituents and metabolites by high-performance liquid chromatography followed by UV detection at 285 nm. The limit of detection is less than 5 ng/ml. Interference with a series of spironolactone and canrenone metabolites was not observed. Plasma levels and renal excretion of canrenone after oral administration of 200 mg of spironolactone and intravenous injection of 200 mg of potassium canrenoate to a healthy male volunteer were measured.
D000284:Administration, Oral; D000328:Adult; D002192:Canrenone / Q000032:analysis* / Q000097:blood / Q000652:urine; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011245:Pregnadienes / Q000032:analysis*; D013056:Spectrophotometry, Ultraviolet; D013148:Spironolactone / Q000378:metabolism*
D011245:Pregnadienes; D013148:Spironolactone; D002192:Canrenone